Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Brown University
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.
The US Veterans Administration is attracting more interest from drugmakers seeking to grow their foothold in the lucrative – but scientifically challenging – market for CNS disorders. The allure comes from VA’s strong analytics and data crunching capabilities as well as its investigatory and trial management expertise in high-profile areas like traumatic brain injury, post-traumatic stress and major depression.
The advanced wound care market is attracting an increasing number of competitors and investors seeking a stake in this high-need, high-growth space. But although the number of innovative wound care products is on the rise, this is also a highly diverse market, with some striking differences among various regions of the world in terms of product adoption and standard wound care practices.
Large numbers of patients with chronic wounds haven’t responded to existing treatments, and their open wounds can have dire consequences. The suffering of patients, the failures of past remedy attempts, and new financial pressures on hospitals have medtech entrepreneurs and venture investors focused on finding better solutions to wound care.
- Academic and Research Institutions